High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma

Cancer

Volumn 107, Issue 1, 2006, Pages 37-45

  Parker, Alexander S ^a   Kosari, Farhad ^b   Lohse, Christine M ^b   Thompson, R Houston ^b   Kwon, Eugene D ^c   Murphy, Linda ^b   Riehle, Darren L ^b   Blute, Michael L ^b   Leibovich, Bradley C ^b   Vasmatzis, George ^b   Cheville, John C ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Clear cell renal cell carcinoma; Nephrectomy; Nuclear grade; Prognostic biomarkers; Protein isoforms; Survivin expression

Indexed keywords

PARAFFIN; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR NECROSIS; TUMOR VOLUME;

AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TREATMENT OUTCOME; UP-REGULATION;

EID: 33745316516     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21952     Document Type: Article

References (36)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Lohse CM, Cheville JC. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med. 2005;25:433-464.
3. Curti BD. Renal cell carcinoma. JAMA. 2004;292:97-100.
4. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163-1167.
5. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405-411.
6. Figlin R, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol. 1997;158:740-745.
7. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative nomogram for renal cell carcinoma. J Urol 2001;166: 63-67.
8. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657.
9. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. J Urol. 2002;168: 2395-2400.
10. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663-1671.
11. Atkins MB, Avigan DE, Bukowski RM, et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004;10(18 Pt 2):6277S-6281S.
12. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005; 173:1853-1862.
13. Kosari F, Parker AS, Kube AM, et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005; 11:5128-5139.
14. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987-989.
15. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumors. J Pathol. 1997;183:131-133.
16. Lohse CM, Blute ML, Zincke H, et al. Comparison of standardized and non-standardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol. 2003;118:877-886.
17. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104:511-520.
18. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435-441.
19. Therneau T, Grambsch, P. Modeling survival data: extending the Cox model. In: Dietz K, Gail M, Krickeberg K, Tsiatis A, Samet J, eds. Statistics for biology and health, 1st ed. Ann Arbor: Springer-Verlag, 2000:87-92.
20. Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2001;2:1-10.
21. Alteri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581-8489.
22. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer. 2005;92:212-216.
23. Okada H. Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Review Cancer. 2004;4:592-603.
24. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097-6102.
25. Mahotka C, Krieg T, Krieg A, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer. 2002;100:30-36.
26. Andersen MH, Thor SP. Survivin-a universal tumor antigen. Histol Histopathol. 2002;17:669-675.
27. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003;12:136-143.
28. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 2003;93:1541-1552.
29. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA. 2001;98:635-640.
30. Yamamoto T, Manome Y, Nakamura M, Tanigawa N. Downregulation of survivin expression by induction of the effector cull protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer. 2002;38:2316-2324.
31. Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and UNA interference. Clin Cancer Res. 2003;9:931-946.
32. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA. 2000;97:13108-13107.
33. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich D. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 2003;9:6523-6533.
34. Reed JC, Wilson DB. Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 2003;9:6523-6533.
35. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Diff. 2002;9:1334-1342.
36. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2003;24:1994-2007.